'Cure models' offer additional information to traditional epidemiological approaches to assess survival for cancer patients by simultaneously estimating the proportion cured and the survival of those 'uncured'. The proportion cured is a summary of long-term survival while the median survival time of the uncured provides important information on those who are not long-term survivors. Population-based trends in the cure proportion and survival of the uncured for childhood acute lymphoblastic leukaemia (ALL) by clinical prognostic risk factors were estimated using flexible parametric cure models, based on overall survival and event-free survival. Children aged 1-17 years diagnosed between 1990 and 2011 in Yorkshire, UK, were included (n = 492). The percentage cured increased from 77% (95% confidence interval 70-84%) in 1990-1997 to 89% (84-93%) in 2003-2011, while the median survival time of the uncured decreased from 3Á2 years (2Á2-4Á1 years) to 0Á7 years (0-1Á5 years). Models based on event-free survival showed a similar trend. The 5-year cumulative incidence of relapse substantially decreased from 35% in 1990-97 to 9% in 2003-2011. These results show selective improvement in survival between 1990 and 2011 with a significant reduction in the risk of relapse alongside a reduced absolute duration of survival for those destined to be uncured.
Summary
'Cure models' offer additional information to traditional epidemiological approaches to assess survival for cancer patients by simultaneously estimating the proportion cured and the survival of those 'uncured'. The proportion cured is a summary of long-term survival while the median survival time of the uncured provides important information on those who are not long-term survivors. Population-based trends in the cure proportion and survival of the uncured for childhood acute lymphoblastic leukaemia (ALL) by clinical prognostic risk factors were estimated using flexible parametric cure models, based on overall survival and event-free survival. Children aged 1-17 years diagnosed between 1990 and 2011 in Yorkshire, UK, were included (n = 492). The percentage cured increased from 77% (95% confidence interval 70-84%) in 1990-1997 to 89% (84-93%) in 2003-2011 , while the median survival time of the uncured decreased from 3Á2 years (2Á2-4Á1 years) to 0Á7 years (0-1Á5 years). Models based on event-free survival showed a similar trend. The 5-year cumulative incidence of relapse substantially decreased from 35% in 1990-97 to 9% in 2003-2011 . These results show selective improvement in survival between 1990 and 2011 with a significant reduction in the risk of relapse alongside a reduced absolute duration of survival for those destined to be uncured.
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Acute lymphoblastic leukaemia (ALL) is the most frequently diagnosed cancer subtype in children, accounting for 25% of all childhood cancers and 79% of all childhood leukaemias (Stiller, 2007) . Five-year survival for ALL has increased substantially since the 1960s, with the EUROCARE-5 study reporting a 5-year survival of 86% for children with ALL diagnosed between 2000 and 2007 (Gatta et al, 2014) .
ALL patients are risk-stratified based on clinical features, including white cell count (WCC), age, sex and, more recently, cytogenetic data (Moorman et al, 2010; Vora et al, 2013) , and survival differences between risk groups are generally based on clinical trial outcomes. Although recruitment into clinical trials for children with ALL in the UK is high, estimated at 85-99% for children (Stiller et al, 2012; van Laar et al, 2015) and 66-77% for those aged 15-17 years (Hough et al, 2017) , survival estimates based on clinical trial outcomes for ALL are not population-based. ALL patients enrolled into clinical trials have been shown to have a survival advantage compared to those not enrolled on trials (Hough et al, 2017; Strahlendorf et al, 2018) . Population based studies on long-term ALL survival, including clinical risk factors, are needed to provide real-world benchmark estimates of prognosis.
Standard statistical methods to assess cancer survival generally analyse all patients as one group. A statistical cure model offers an alternative approach to provide additional insights into survival trends by assuming there are two groups of patients: one who do not experience the outcome of interest and are 'cured' and the other who do experience the outcome (the 'uncured') and their survival is estimated separately (Sposto, 2002; Lambert et al, 2007; Othus et al, 2012) . Cure is measured at the population level and is defined as the proportion of patients as a group for whom there is no excess mortality compared to the general population. The proportion cured is an estimate of longterm survival but cure models also allow the survival of patients who are not long-term survivors to be investigated. Covariates may have different association with patients who are cured and those who are not. Furthermore, they are useful when investigating temporal trends in survival. For example, if survival has increased over time, cure models can provide additional information on whether this was because the proportion of patients cured over time increased, or because the survival time of those patients who will eventually die increased or a combination of both (Verdecchia et al, 1998; Yu et al, 2013) .
Cure models have previously been applied to children with ALL and found that the proportion of children cured has increased steadily since the 1970s (Shah et al, 2008; Gatta et al, 2013) . However, they have not been utilised to describe either population-based trends in 'uncured' individuals or event-free survival (EFS), or estimate the proportion cured by clinical prognostic risk factors. Furthermore, estimates of the proportion cured have not been reported for children with ALL diagnosed since 2002.
The aims of this study were to utilise population-based data to estimate the cure proportion, trends in EFS and median survival time of the uncured in children diagnosed with ALL between 1990 and 2011, including trends by clinical risk stratification variables including cytogenetic risk group.
Materials and methods

Study population
Data were extracted from the Yorkshire Specialist Register of Cancer in Children and Young People (YSRCCYP; http:// medhealth.leeds.ac.uk/info/545/yorkshire_specialist_cancer_re gister/), a population-based database of children and young people (0-29 years) diagnosed with cancer residing in the Yorkshire and Humber region in the north of England, covering a population of approximately 2 million 0-to 29-year olds. The primary source of ascertainment was hospital records with secondary sources including neuropathology reports, hospital admissions and other regional and national cancer registries (van Laar et al, 2010) . All patients were proactively followed-up every 2 years to ascertain their vital status with minimal loss to follow-up. Relapse information is received through direct notifications from the cancer centre and via the biennial follow-up of patients. The YSRCCYP has ethical approval from the Northern and Yorkshire Multi Centre Research Ethics Committee (MREC) and approval under section 251 of the NHS Act (2006) for holding identifiable patient data from the Health Research Authority Confidentiality Advisory Group.
We identified all patients diagnosed with ALL, corresponding to the International Classification of Childhood Cancer 3rd Edition group Ia (Steliarova-Foucher et al, 2005) , between October 1990 and June 2011 aged 1-17 years (i.e., before 18th birthday) (to coincide with the availability of national ALL clinical trials). This age range was included rather than the commonly used childhood age range of 0-14 years, as it reflects the paediatric age range treated in clinical practice at the hospitals in the study region. This was also the upper age limit of the UKALL 2003 trial, which opened in 2003, although this increased to 20 years in 2006 and to 24 years from 2007 onwards (Vora et al, 2013) ; 18-to 24-year-old ALL patients have been excluded from this study as they were treated on different protocols prior to 2006.
Relapse was defined as recurrent disease either occurring locally at the same site as the initial diagnosis and/or elsewhere (Feltbower et al, 2007) . The exact date of relapse was extracted for analysis.
Trends over time were assessed using three time periods corresponding to the recruitment periods of the three main trials for ALL in the UK: UKALL XI from October 1990 to March 1997 (Hann et al, 2001 ), ALL97 and ALL97/99 from April 1997 to September 2003 (Mitchell et al, 2005 (Mitchell et al, , 2009 Vora et al, 2006) and UKALL2003 from October 2003 to June 2011 (Vora et al, 2013) . Within the ALL97 trial, the duration and treatment intensity changed in November 1999 (with this phase known as ALL97/99) (Mitchell et al, 2009 ), however we were unable to consider these two separate subperiods due to sample size restrictions.
Patient sex, age at diagnosis (1-9 years, ≥10 years) and WCC at diagnosis (<50 9 10 9 /l, ≥50 9 10 9 /l) were extracted from the database and included as prognostic risk factors as these are used in clinical practice for risk stratification (Vora et al, 2013) . Patients with missing WCC were excluded from analysis (n = 26, 5%).
For a subset of patients recruited into clinical trials we obtained their cytogenetic risk group via linkage to the Leukaemia Research Cytogenetics Group database (https://resea rch.ncl.ac.uk/lrcg/). Patients were matched on personal identifiers, including NHS number, patient names, date of birth and sex. Cytogenetic risk group was coded as good, intermediate or poor for B cell precursor ALL and all T cell precursor ALL were included in one group (Moorman et al, 2010) . For some patients after linkage we were unable to obtain their risk group (categorised as "Unknown"). The characteristics of patients with and without cytogenetic data are shown in Table SI .
All cases were followed-up to 31 December 2016, providing at least 5 years follow-up for each patient. Overall survival (OS) was defined from date of diagnosis to date of death or censoring. EFS was defined from date of diagnosis to date of relapse or date of death, whichever occurred first.
Statistical methods
Overall survival and EFS were examined by prognostic risk factors (period of diagnosis, age, sex, WCC and cytogenetic risk group) and graphically by Kaplan Meier survival curves.
Flexible parametric cure models were used to estimate the proportion cured and the median survival time of the uncured (Andersson et al, 2011) . Models were based on both OS and EFS. Models based on OS were modelled in the relative survival framework. Relative survival is defined as the observed survival divided by the expected survival where the expected survival is obtained from national life tables stratified by age, sex and calendar year. If the relative survival function reaches a plateau at some point after diagnosis then the excess hazard is zero and the cancer patients still alive experience the same survival as the general population and are considered statistically cured. The median survival time (MST) of the 'uncured' was estimated simultaneously from the model. The proportion cured provides an estimate of long-term survival while the MST of the uncured gives information on those who are not long-term survivors.
Covariates were included as time-varying coefficients so that the proportion cured and the survival function of the uncured varied by covariates. Excess mortality rate ratios (EMRR), which are equivalent to the hazard ratio from a Cox model, were estimated from the cure model and allow examination of the association of covariates on survival and cure. Models for OS were fitted in the relative survival framework using national lifetables for England obtained from the Office for National Statistics (Office for National Statistics 2017).
Each risk factor (period of diagnosis, age, sex and WCC) was included in a univariable model and a fully adjusted model including all the covariates. The cure model provides estimates separately for each combination of covariates in the model, therefore to make comparisons between levels of each covariate while adjusting for the others we calculated standardised estimates (Andersson et al, 2014; Eriksson et al, 2016) . For example, the cure proportion for each sex was estimated assuming that the distribution of the other covariates (age, period of diagnosis and WCC) was the same as the whole study population. Standardised estimates were calculated for both the cure proportion and MST for both OS and EFS. All survival estimates and the proportion cured are presented as percentages rather than proportions.
Sensitivity analysis was conducted to compare results from the cure model to a survival model without the assumption of 'cure'. Univariable and multivariable flexible parametric survival models (Royston & Lambert, 2011) were included for each risk factor as described above.
Further cure models including cytogenetic risk group were estimated, including those with unknown cytogenetic risk group and those we were unable to link as separate categories.
The cumulative incidence of relapse was estimated by time period with death as a competing risk (Coviello & Boggess, 2004) .
Results
A total of 492 patients were included, of whom 81 (17%) died and 90 (18%) relapsed within the follow-up period (Table I) . The median time from diagnosis to relapse was 2Á5 years III, Fig 1) . The survival curves tended to flatten out around 8-10 years after diagnosis.
For relative survival, the adjusted excess mortality rate ratio (EMRR) was 55% lower in 2003-2011 compared to 1990-97 [Adjusted EMRR = 0Á45 (95% CI 0Á26, 0Á80), Table II ]. The standardised percentage cured increased from 77% (95% CI 70, 84) in 1990-97 to 89% (95% CI 84, 93) in 2003-2011 while the median survival time of the uncured decreased from 3Á2 years (95% CI 2Á2, 4Á1) to 0Á7 years (95 CI 0, 1Á5) over this time period. There were significant differences in the percentage cured by WCC: 87% (95% CI 84, 90) for those with lower WCC and 72% (95% CI 63, 81) for those with higher WCC. There were no differences in the percentage cured by age or sex and no differences in the median survival time of the uncured by age, sex or white cell count (Table II, Table SII) . Table III shows results of the EFS models. In these models, the percentage cured defines the group of patients free from relapse or who have not died. The overall trends by risk factor are similar to the model for OS except that the estimates of the percentage cured are slightly lower in the EFS model. The percentage cured increased from 58% (95% CI 49, 66) in 1990-97 to 86% (95% CI 81, 91) in 2003-2011 while the median survival of the uncured decreased slightly, from 2Á5 years (95% CI 2Á1, 2Á9) to 1Á3 years (95% CI 0Á2, 2Á5).
Based on cytogenetic risk group, the percentage cured was 90% for patients in the good risk group (95% CI 85, 94), 76% for intermediate risk group (95% CI 67, 82), 65% for high risk group (95% CI 42, 81) and 78% for patients with T cell ALL (95% CI 63, 88) (Table IV, Figure S1 ).
There was a substantial reduction in the risk of relapse over time; 5-year after diagnosis the cumulative incidence of relapse fell from 35% (95% CI 28, 42) for those diagnosed 1990-97 to 9% (95% CI 6, 14) for those diagnosed 2003-2011 (Fig 2) .
Discussion
Utilising a 'cure' model to evaluate population-based data we have confirmed an increase in the proportion of patients diagnosed with childhood ALL who have been cured with more contemporary therapeutic approaches. However, there remained a relatively small group of patients where treatment was unsuccessful and whose survival was relatively short; the median survival time of the uncured diagnosed in most recent time period was around 1 year. The survival trends of patients who are not long-term survivors (the uncured) have not been described before, and the interpretation of trends in the survival of the uncured is difficult. Improvements in risk stratification and minimal residual disease monitoring (Vora Table II . 5-year relative survival, excess mortality rate ratios, percentage cured and median survival time of uncured [including 95% confidence intervals (CI)] based on overall survival for acute lymphoblastic leukaemia patients. (Ederer et al, 1961) . Adjusted estimates are presented for each variable assuming that the distribution of the other variables is the same as the whole study population, therefore allowing direct comparison between groups.
et al, 2013) will have led to more patients moving to the cured group, leaving the most chemo-resistant patients in the uncured group. Due to the high proportion of patients 'cured', these estimates are based on a relatively small sample size and should be interpreted with caution. Key prognostic post-relapse factors are duration of first remission, site of relapse and genetic subgroup (Irving et al, 2016) . This small group of 'uncured' patients may contain a heterogeneous group in terms of molecular genetics and further investigation and examination of in this group is needed. Additionally, utilising this approach for the first time in population-based data, we have been able to identify an increase in the proportion cured over time based on EFS. This would appear to be a consequence of a significant reduction in the risk of relapse over time. Population-based estimates of EFS for ALL patients have not previously been reported, mainly due to lack of routinely collected data on relapse. Our estimates of 5-year population-based EFS for ALL patients are similar to those reported in national clinical trials: between October 1990 and March 1997 the estimated 5-year EFS was 62% compared with 63% reported in the UKALLXI study (Hann et al, 2001) ; between April 1997 and September 2003 the estimated 5-year EFS was 80%, compared to 74% for the ALL97 study and 80% for the ALL97/ Table III . 5-year event-free survival, excess mortality rate ratios, percentage cured and median survival time of uncured [including 95% confidence intervals (CI)] based on relapse-free survival for acute lymphoblastic leukaemia patients. Adjusted estimates are presented for each variable assuming that the distribution of the other variables is the same as the whole study population, therefore allowing direct comparison between groups. 99 study (Mitchell et al, 2009; Moorman et al, 2010) ; and between October 2003 and June 2011 the estimated 5-year EFS was 86% compared to 87% reported by the UKALL2003 study (Vora et al, 2013) . Similarly, the UKALL2003 study found a 5-year cumulative incidence of relapse of 9% (Vora et al, 2013) compared to our findings of 6% during the same time period although we did not include those aged 18-24 years in our study but they were included in UKALL2003. These findings provide evidence of the validity of our estimates and completeness of the ascertainment of relapse data for the population-based YSRCCYP and the potential to use routine cancer registry data to estimate long-term relapse incidence and EFS. Cytogenetic information is important not only for predicting survival but also to identify patients at increased risk of relapse and those less likely to respond to treatment after relapse (Irving et al, 2016) . Cancer registries do not routinely collect this information, so this is a unique feature of this study and a major strength, although there may have been changes to cytogenetic information available over time. Fiveyear OS for those in the good risk group in patients in the ALL97/99 trial was 94% (Moorman et al, 2010) : we estimated the proportion cured in this risk group to be 91%, providing valuable information on the long-term survival for this group of patients.
5-year EFS
For patients diagnosed between 2003 and 2011, the 5-year survival estimate was very similar to the percentage of patients cured. The proportion cured for childhood ALL has been increasing since the 1970s, reflecting major improvements in survival during this time (Shah et al, 2008; Gatta et al, 2013) . We have shown that this increasing trend continued including patients diagnosed up to 2011, however the rate of increase may have slowed down; between 1997-2003 and 2003-2011 the proportion cured increased from 84 to 89%. This is consistent with population-based survival trends reported by clinical trial era (Stiller et al, 2012; van Laar et al, 2015) .
The estimates of the association between risk factors and OS and EFS were similar for the cure model and the survival model that does not assume cure (Table S3) , however additional information on different aspects of survival can be obtained from the cure model by considering separately the trends for the 'cured' and 'uncured'. The proportion cured is a useful measure of long-term survival and may be more informative for communicating prognosis to patients rather than focussing on the benchmark of 5-year survival.
Key strengths of this study are the availability of population-based clinical data including cytogenetic risk group, T-ALL, T cell acute lymphoblastic leukaemia.
despite this not being available for all patients. Our data showed that the survival curves tended to flatten out after 8-10 years follow-up but there may remain some excess mortality after this, suggesting that, particularly for more recently diagnosed patients, a longer follow-up period may be needed. Other study limitations are that cure could not be estimated for all subgroups due to limited sample size. A larger sample would allow the examination of trends over time by patient subgroups. This study only included patients diagnosed in one region in England, however the Yorkshire region is representative of England and Wales in terms of socio-demographics (Feltbower et al, 2004) . Replication of this approach in national disease registries is needed. Statistical cure is measured at the population level and does not provide information on individual level cure. Overall survival, and even EFS, do not measure quality of survival (Barr & Sala, 2005) . Childhood cancer survivors are at risk of an array of late effects of treatment, including excess late mortality (Armstrong et al, 2016; Fidler et al, 2016) , subsequent malignant neoplasms (Olsen et al, 2009; Friedman et al, 2010; Reulen et al, 2011) , as well as other morbidities which may not occur until many decades after the end of treatment (Oeffinger & Robison, 2007) . Available data to monitor and identify these late effects are not routinely recorded within population-based cancer registries. Nonetheless, through data linkage to routinely collected primary and secondary care records there is the potential to explore these outcomes for long-term survivors and assess 'cure' based not only on survival outcomes but also through incorporating other adverse late health effects to account for these in the definition and statistical modelling of cure (Zwaan & Sposto, 2013) .
In conclusion, an innovative analytical approach utilising cure models has identified a reduction in relapse risk alongside a reduced absolute duration of survival for those with ALL destined to be uncured.
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